Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript

Operator

Good day, and welcome to the TX45 Phase Ib Part B PH-HFrEF data conference call. [Operator Instructions] As a reminder, this call may be recorded.

I would now like to turn the call over to Dr. Alise Reicin. Please go ahead.

Alise Reicin
President, CEO, Secretary & Director

Thank you. Good afternoon, and thank you for joining us. Today, we’ll be reviewing the top line results from Part B of our Phase Ib clinical trial, which evaluated the safety and hemodynamic effects associated with a single dose of TX45 in patients with pulmonary hypertension associated with reduced ejection fraction heart failure, and we’ll be referring to this as PH-HFrEF . Next slide, please.

Attached is our disclaimer information regarding forward-looking statements that will be made today. Next slide.

This 14-patient clinical trial was designed to evaluate the safety and tolerability of TX45 in patients with PH-HFrEF and to explore the hemodynamic effects of TX45 in this patient population. I’ve been asked over the — several times over the last few months, what do I hope to see in this trial? And the goal was to observe hemodynamic effects that were directionally similar to what was seen in